RPS6KA5

Across TCGA pan-cancer cohorts, RPS6KA5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPS6KA5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RPS6KA5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RPS6KA5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where RPS6KA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.914	0.634	<.001	39	view →
CCRCC	DFS	Quartile	II,III,IV	0.787	0.317	.003	27	view →
LUAD	OS	Tertile	All	0.935	0.694	.001	16	view →
PDAC	DFS	Quartile	II,III,IV	0.583	0.780	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPS6KA5–LSCC (OS)

Open the LSCC breakdown →